Showing results (101-110 of 144) with videos related to
Sort By:
Pageof 15
Neuroscience|April 1, 1994
Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous systemH De Vos, G Bricca, J De Keyser, et al.Journal of Neurology|March 14, 2008
Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic strokeM Uyttenboogaart, M W Koch, K Koopman, et al.Neurology|September 12, 2001
Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO productionE A Beenakker, T I Oparina, A Hartgring, et al.Clinical Neuropharmacology|October 1, 1994
Bromocriptine therapy in multiple sclerosis: an open label pilot studyV Bissay, N De Klippel, L Herroelen, et al.European Journal of Neurology|April 18, 2007
Plasma lipid peroxidation and progression of disability in multiple sclerosisM Koch, J Mostert, A V Arutjunyan, et al.European Radiology|April 5, 2008
Reproducibility over a 1-month period of 1H-MR spectroscopic imaging NAA/Cr ratios in clinically stable multiple sclerosis patientsJ P Mostert, Y Blaauw, M W Koch, et al.Journal of the Neurological Sciences|October 1, 2008
Development and validation of a predictive outcome score of cerebral venous thrombosisK Koopman, M Uyttenboogaart, P C Vroomen, et al.Neuroscience|July 28, 2014
β₂-adrenergic receptors protect axons during energetic stress but do not influence basal glio-axonal lactate shuttling in mouse white matterG Laureys, M Valentino, F Demol, et al.Nature Communications|June 25, 2022
Identification and characterization of a new ensemble of cometary organic moleculesN Hänni, K Altwegg, M Combi, et al.European Journal of Neurology|October 25, 2007
Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosisJ P Mostert, J C de Groot, G S M Ramsaransing, et al.Pageof 15